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Molecular Remission in PML/RARa-Positive Acute Promyelocytic Leukemia
by Combined MV-trans Retinoic Acid 
and Idarubicin (AIDA) Therapy
By Franco Mandelli, Daniela Diverio, Giuseppe Avvisati, Anna Luciano, Tiziano Barbui, Carlo Bernasconi, 
Giorgio Broccia, Raffaella Cerri, Michele Falda, Giuseppe Fioritoni, Franco Leoni, Vincenzo Liso, 
Maria Concetta Petti, Francesco Rodeghiero, Giuseppe Saglio, Maria Luce Vegna, Giuseppe Visani, Ulrich Jehn, 
Roel Willemze, Petra Muus, Pier Giuseppe Pelicci, Andrea Biondi, and Francesco Lo Coco for thè Gruppo Italiano 
Malattie Ematologiche Maligne dell' Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica 
Cooperative Groups
Two hundred fifty-three patients with newly diagnosed 
acute promyelocytic leukemia (APL) were eligible to enter 
the multicentric GIMEMA-AIEOP "AIDA" trial during the pe­
riod July 1993 to February 1996. As a mandatory prerequisite 
for eligibility, all patients had genetic evidence of the specific 
t(15;17) lesion in their leukemic cells confirmed by karyotyp­
ing or by reverse transcription-polymerase chain reaction 
(RT-PCR) of the PML/RARa fusion gene (the latter available 
in 247 cases). Median age was 37.8 years (range, 2.2 to 73.9). 
Induction treatment consisted of oral all-trans retinoic acid 
(ATRA), 45 mg/m2/d until complete remission (CR), given 
with intravenous Idarubicin, 12 mg/m2/d on days 2,4, 6, and
8. Three polychemotherapy cycles were given as consolida­
tion. Hematologic and molecular response by RT-PCR was 
assessed after induction and after consolidation. At the time 
of analysis, 240 of the 253 eligible patients were evaluable
for induction. Of these, 11 (5%) died of early complications 
and 229 (95%) achieved hematologic remission. No cases of 
resistant leukemia were observed. Of 139 cases studied by 
RT-PCR after induction, 84 (60.5%) were PCR-negative and 55 
(39.5%) PCR-positive. One hundred sixty-two patients were 
evaluable by RT-PCR at the end of consolidation. Of these, 
159 (98%) tested PCR-negative and 3 (2%), PCR-positive. 
After a median follow up of 12 months (range, 0 to 33), the 
estimated actuarial event-free survival for the whole series 
of 253 eligible patients was 83% ± 2.6% and 79% ± 3.2% at
1 and 2 years, respectively. This study indicates that the 
AIDA protocol is a well-tolerated regimen that induces mo­
lecular remission in almost all patients with PML/RARa-pos- 
itive APL. Preliminary survival data suggest that a remark­
able cure rate can be obtained with this treatment.
1997 by The American Society of Hematology.
ACUTE PROMYELOCYTIC leukemia (APL) is a particu­lar type of acute myeloid leukemia (AML) with char­
acteristic biological and clinical features, which include the 
presence of a specific t(l5; 17) chromosome translocation in
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the leukemic blasts, the frequent association at diagnosis of 
a severe hemorrhagic diathesis, and in vitro and in vivo 
sensitivity to the differentiating agent all-trans retinoic acid
(ATRA).1'4
The t(15; 17) involves the retinoic acid receptor a  (RARa) 
gene on chromosome 17 and the PML (for promyelocytic) 
gene on chromosome 15 and generates a chimeric gene, 
which is transcribed into the PML/RARa fusion transcript. 
The resulting PML/RARa chimeric protein is crucial to the 
pathogenesis of the disease.3,4
The PML/RARo: hybrid mRNA is readily detectable by 
the reverse transcription-polymerase chain reaction (RT-PCR)
5,6 As reported by several groups, including ours, RT-
PCR studies of the PML/RAR« have proved extremely useful 
in the clinical management of the disease.5'11 Detection of 
PML/RARo; at diagnosis predicts response to ATRA, whereas 
cases with morphological features of APL, which are PML/ 
RARa negative, are refractory to differentiative treatment.6 
Moreover, when they are applied to evaluating residual dis­
ease during remission, RT-PCR tests can identify patients at 
risk of relapse and in need of additional therapy.7'11
Anthracycline-based chemotherapy (CHT) and ATRA are 
the mainstay of APL treatment.2'4 Anthracyclines alone or 
in association with cytosine arabinoside induce complete 
remission (CR) in a high percentage of cases (75% to 80%),
but this approach is associated with a high mortality rate (up 
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entiative treatment with ATRA results in greater than 90% 
CRs, but patients remain invariably PCR positive after induc­
tion, and all relapse if no consolidation CHT is added.2'4,18'21 
Furthermore, ATRA treatment has been associated with the 
occurrence, in a sizable fraction of patients, of life-threaten­
ing complications. These include a severe respiratory distress 
due to pulmonary infiltrates (ATRA syndrome) usually (but
1014 Blood, Voi 90, No 3 (August 1), 1997: pp 1014-1021
MOLECULAR REMISSION IN PML/RARa +ve APL 1015
not uniformly) correlated to a rapid increase of white blood 
cell counts21,22 and pseudotumor cerebri, which is more fre­
quently observed in younger patients.23
Preliminary clinical studies have been performed with var­
ious combinations of ATRA and CHT in an attempt to obtain 
more durable remissions and reduced ATRA-related toxicity. 
The combinations, as demonstrated in a randomized trial, 
seem to improve disease-free survival over that achieved
signs and symptoms of the above mentioned ± lower extremities 
edema and hypotension. In all other patients, the ATRA syndrome 
was defined as “ definitely absent.” 211 Rules for supportive therapy, 
treatment of the ATRA syndrome, and prevention and control of the 
coagulopathy have been reported in detail elsewhere.26
Collection and preparation o f samples fo r  molecular studies. 
Samples for RT-PCR analyses were requested at diagnosis, at the 
time of CR after induction, and at the end of consolidation. With the 
exception of some cases with hyperleukocytosis in which peripheral
w ith chem otherapy alone.*4 S ince 1983, the Italian coopera- blood (PB) samples were studied at presentation, all other diagnostic
tive group, Gruppo Italiano Malattie Ematologiche Maligne 
dell’ Adulto (GIMEMA), adopted disease-tailored protocols 
for APL, showing that anthracydines alone are as effective 
in inducing remission as polychemotherapy schemes.25 In
aiming at improving the efficacy of APL-targeted 
treatment, a new protocol combining ATRA and Idarubicin 
(AIDA protocol) was designed by the GIMEMA, first as a 
pilot,20 then in association with the Associazione Italiana di 
Ematologia ed Oncologia Pediatrica (AIEOP), as a larger 
multicentric study. Prospective RT-PCR analyses were per- for RT-PCR studies (Hematology, University “ La Sapienza” of
and all remission samples were obtained from the bone marrow 
(BM). Mononuclear cells, obtained by centrifuging BM or PB speci­
mens on a Ficoll-Hypaque density gradient, were washed twice in 
sterile phosphate-buffered saline (PBS), suspended in a 4-mol/L gua- 
nidium thiocyanate (GTC) solution and stored at ~2C)°C. These pro­
cedures were performed in each GIMEMA and AIEOP center using 
RNAase-free disposable materials. The GTC solution was previously 
prepared by the referral molecular biology laboratories and distrib­
uted to all peripheral centers. Samples cryopreserved in GTC were 
then sent in dry ice to two referral molecular biology laboratories
formed on all patients at presentation to assess study eligibil­
ity and after treatment to better evaluate response and mini­
mal residual disease.
MATERIALS AND METHODS
Patients. Two hundred seventy-four consecutive patients with 
newly diagnosed APL were registered during the period July 1993 to 
February 1996. All cases were diagnosed as AML French-American- 
British (FAB) M3 or M3 variant (M3v) by conventional morphocy- 
tochemical criteria27 in 71 participating institutions (see Appendix). 
The majority of these centers belong to the Italian cooperative groups 
GIMEMA and AIEOP, while five belong to other European coun­
tries. Eligibility criteria to be enrolled in the AIDA protocol included: 
age between 1 and 75 years, karyotypic and/or molecular evidence 
of the t( 15; 17) in leukemic blasts at presentation, serum creatinine 
<2.5 mg/dL, serum alkaline phosphatase, bilirubin, and aspartate 
aminotransferase (AST) <3 times the upper normal limit, no cardiac 
contraindications to anthracycline chemotherapy, negative preg­
nancy test, and informed consent. Cases presenting with hyperleuko­
cytosis were also included in the study.
AIDA protocol. Induction therapy consisted of 45 mg/nr/d 
ATRA administered orally until the achievement of CR or for a 
maximum of 90 days, and four 12 m g/nr doses of Idarubicin given 
intravenously (IV) on days 2, 4, 6, and 8. In patients less than
20 years old, ATRA doses were adjusted to 25 mg/m2. After the 
achievement of hematologic remission, patients received three con­
solidation polychemotherapy courses as reported .E ach  consolida­
tion course was administered at recovery from the previous course, 
when polymorphonuclear cells and platelet counts were >l,500/p.L 
and >  1 (X),00()/jwL, respectively.
At the end of consolidation, residual disease was estimated by RT- 
PCR before deciding further therapy. PCR-negative patients were 
randomized into four arms including chemotherapy alone with 6- 
mercaptopurine and methotrexate (arm I), ATRA alone (arm 2), 
alternating chemotherapy and ATRA (arm 3), or no further therapy 
(arm 4). Patients who were PCR-positive underwent, if eligible, 
allogeneic bone marrow transplantation in first CR.
ATRA syndrome was defined as “ definitely present’’ or “ overt” 
in the presence of the following five signs and symptoms: fever, 
dyspnea, pleural and/or pericardial effusion, pulmonary infiltrates 
on chest radiograph, and unexplained weight gain greater than 5 kg, 
according to the original report by Frankel et al. We defined as 
“ indeterminate” ATRA syndrome a combination of two to four
Rome and Clinica Pediatrica, University of Milano, Monza).
RT-PCR o f PML/RARa. Total RNA was extracted by the method 
of Chomczynsky and Sacchi.29 The integrity of RNAs was assessed 
in all diagnostic and remission samples by electrophoretic run 
through a formaldehyde minigel. The protocol and the primers used 
to amplify the PML/RARa hybrid gene have been reported else­
where.7 To assess the efficiency of the RT step and to farther verify 
RNA integrity, a cDNA fragment containing RARa exons 2 and 3 
was coamplified in each analyzed sample (internal control). A posi­
tive control (amplification of RNA extracted from the promyelocytic 
cell line NB4) and a negative control (all reagents plus water with
no RNA) was included in each experiment. To assess the sensitivity 
of our RT-PCR method, total RNA isolated from a diagnostic sample 
with 100% blastic infiltration was serially diluted by mixing it with 
the t( 15; 17) negative myeloid cell line GF-D8 RNA/ Our assay 
allowed us to detect the PML/RARa transcript in the presence of
0.1 ng total RNA, that is a final dilution of 10
Evaluation o f response. CR was defined as the reconstitution of 
normal BM cellularity with less than 5% leukemic promyelocytes, 
together with PB cell counts of polymorphonuclear leukocytes 
(PMN) >  l,500//iLand platelets >  10(),()00//iL. Molecular remission 
was defined as the disappearance, on ethidium bromide-stained elec­
trophoresis gel, of the specific PML/RARa amplification band iden­
tified at diagnosis, in the presence of RNA integrity as evaluated by 
minigel visualization and successful amplification of the internal 
control. Overall survival (OS) and event-free survival (EPS) duration 
was calculated by the method of Kaplan and Meier. The median 
observation was 12 months (range, 0 to 33).
RESULTS
Patient characteristics at diagnosis. Of the 274 patients 
registered, 21 (7.7%) were considered ineligible. Exclusion 
criteria for these 21 patients are reported in Table 1. These
21 patients were withdrawn from the study and treated differ­
ently.
The clinical and biological characteristics of the 253 eligi­
ble patients are shown in Table 2. Median age was 37.8
*e, 2.2 to 73.9). Thirty-two cases (12.6%) were 
as microgranular or variant (M3v) APL on mor-
(WBC)
years
phologic exam ination. The m edian w hite blood
count was 2.5 X 107L (range, 0.2 to 140.0). 
toms were present at diagnosis in 67% of patients; of these,
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Table 1. Reasons, Other Than Age, for the Exclusion From Entering 
the AIDA Protocol in 21 Patients Registered as AML-FAB M3
Table 3. Response to Induction Therapy
Exclusion Criteria No. of Cases
Karyotype NA*/PML-RARa;-negative
Karyotype NA/PML-RARa NEt 
Karyotype NEi/PML-RARa-negative 
Absence of t( 15; 17)/PML-RARa-negative 
Absence of t(15;17)/PML-RARa NE 
Karyotype NA/specimen for RT-PCR not sent 
t( 11; 17)/PM L-R ARa-negative 
HIV-positive
Poor performance status/active serious infection 
Other concomitant malignancy
7
3
2
2
2
1
1
1
1
1
Abbreviations: NA, not available; HIV, human immunodeficiency
virus.
* Karyotype, not available, 
t PML-RARa NE, poor quality RNA.
$ Karyotype NE, no mitosis or poor quality metaphases.
94% also had laboratory evidence of coagulopathy defined as 
fibrinogen <150 mg/dL and fibrinogen degradation products 
(FDP) >40 /¿g/mL or D-dimers (XDP) >400 figlmL.
The type of PML/RARa transcript as detected by RT- 
PCR (available in 247 cases) was bcrl-2 (or long type) in 
152 (61.5%) patients, and bcr3 (or short type) in 95 (38.5%) 
patients. In the remaining six eligible patients, the t(15;17) 
abnormality was detected by karyotypic examination only 
and no material was available for molecular studies at diag­
nosis. The type of PML breakpoint was not significantly 
correlated with age, sex, WBC count, or presence of coagu­
lopathy at presentation. However, the incidence of bcr3 was 
significantly higher in patients with a diagnosis of M3v. In 
fact, a bcr3 breakpoint was observed in 20 of 32 (62%) M3v 
cases and in 75 of 215 (35%) hypergranular APL cases (P 
= .005).
Hematological and molecular response to induction ther­
apy. Of the 253 eligible patients, three died of intracranial 
hemorrhage before the start treatment, one was lost to follow 
up, two were crossed to chemotherapy at days +16 and 
4-20 due to ATRA toxicity and were considered as protocol 
violations, and it was too early for response to induction to 
be evaluated in seven patients.
Of the remaining 240 evaluable patients, 229 (95%) com-
Table 2. Clinical and Biological Features of Eligible Patients
at Diagnosis
Sex
M
F
Age median 
(range)
FAB M3 
M3v
WBC X 109/L median 
(range)
Type of PML/RARa transcript 
Long (ber 1-2)
Short (ber 3)
NA
138 (54.5%) 
115 (45.5%) 
37.8 
2.2-73.9 
221 (86.4%) 
32 (12.6%) 
2.5
0.2-140.0
152 (61.5%) 
95 (38.5%) 
6*
Eligible 253
Pretherapy deaths 3
Lost to follow-up 1
Violation 2
Too early 7
Evaluable 240
CR 229 (95%)
Induction deaths 11 (5%)
Resistant disease 0
Abbreviation: NA, not available.
*  All had the t(15;17).
pleted induction therapy and achieved hematologic CR, and
11 patients (5%) died during induction. No cases of resistant 
disease were documented. Of the 11 early deaths, eight were 
due to intracranial hemorrhage and occurred at days + 1, + 1, 
+3, +7, + 8, + 8, +13, and +36, respectively; one to ATRA 
syndrome (day +17), one to cerebral thrombosis (day +13), 
and one to myocardial infarction (day +20). The median 
time of ATRA therapy was 31 days (range, 3 to 90). The 
median time for polymorphonuclear cells to recover to > 1.0 
X 109/L and platelets to >100 X 109/L was 27 days (range,
4 to 48) and 28 days (range, 9 to 49), respectively. Table 3 
shows clinical results after induction.
RT-PCR analysis for the evaluation of the PML/RARa 
hybrid at the end of induction and before consolidation ther­
apy was performed in 139 cases. As to the other patients 
who achieved CR, four cases were not evaluable due to poor 
quality RNA and no samples were sent in for the remaining 
cases. Fifty-five (39.5%) of the 139 patients analyzed in CR 
after induction were PCR-positive and 84 (60.5%) PCR- 
negative. There was no significant correlation between the 
type of PML breakpoint and molecular response to induction 
therapy.
Molecular response after consolidation and follow-up 
analysis. Of the 229 patients who entered hematologic CR,
5 died of complications during consolidation, 1 was lost to 
follow up, 1 relapsed after the second cycle, and 60 have 
yet to complete consolidation therapy. Of the remaining 162 
tested by RT-PCR after consolidation, 159 (98%) were PCR- 
negative and three (2%) PCR-positive. The three PCR-posi­
tive patients had all been positive at the end of induction. 
The remaining 52 patients who had been PCR-positive at 
the end of induction converted to PCR negativity after con­
solidation.
PCR assays between cycles of consolidation were per­
formed in a limited number of cases in this study. Of 23 
patients PCR-positive postinduction, 16 (69.5%) converted 
to PCR-negative and 7 (30.5%) remained PCR-positive after 
the first consolidation. Of these seven PCR-positive, 2 were 
still PCR-positive and 2 converted to PCR-negative follow­
ing the second consolidation (no analyses were available at 
this time in the other three cases. However, all three con­
verted to PCR-negative after the third cycle). In summary, 
of 20 postinduction PCR-positive cases tested either after 
one or two consolidation cycles, 18 (90%) achieved molecu­
lar remission before receiving the third chemotherapy con­
solidation course.
Sixteen (9.8%) of the 162 patients evaluable after consoli­
dation did not complete the three courses because of therapy- 
related toxicity. Clinical and molecular data available in this
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Table 4. Clinical and Molecular Outcome of 16 Patients Withdrawn From Study Due To Therapy-Related Toxicity
UPN Age
No. of Consoiid. 
Cycles Received Type of Toxicity
Further Therapy 
Postconsolid. Outcome
Follow-up RT-PCR 
Analyses
28024 65 0* Cardiac ATRA/MTX/6MP CCR 144-1 Negative (2 tests)
28030 60 0 Infectious ATRA/MTX/6MP CCR 10+ Negative <2 tests)
04003 63 1 Infectious IFN CCR 33+ Negative <3 tests)
10004 62 1 infectious None Relapsed at 6 mo/dead Negative (2 tests)
35003 55 2 Neurologic None CCR 31 + Negative (5 tests)
04002 33 2 Infectious ATRA/MTX/6MP CCR 32+ Negative (3 tests)
36001 59 2 Infectious IFN CCR 324“ Negative (4 tests)
28015 63 2 Prolonged BM  hypoplasia MTX/6MP CCR 334- Negative (6 tests)
D6004 9 2 Severe mucositis None CCR 29+ Negative (6 tests)
43002 66 2 Prolonged BM  hypoplasia None CCR 29 f* Negative (4 tests)
37005 62 2 Prolonged BM  hypoplasia None CCR 304- Negative {5 tests)
55001 43 2 Infectious None Relapsed at 7 mo/dead Positive after ind.t
07006 63 2 Infectious None Dead at 2 mo§ Negative (1 test)
43005 66 2 Neurologic None CCR 16+ Negative (3 tests)
28021 23 2 Infectious MTX/6MP CCR 17 + Negative 5 tests, 1
+ve |
08005 31 2 Infectious None CCR 10+ Negative (3 tests)
Abbreviations: MTX, methotrexate; 6MP, 6-mercaptopurine; IFN, alpha 2b interferon. 
* Patients 1 and 2 received induction therapy only, 
t  Months in continuous complete remission, 
t  Tested after induction therapy only.
§ Died of septic shock while in CR.
| Tested PCR-positive at the last molecular follow-up analysis.
series are shown in Table 4. Median age was 61 years. In 
the majority of cases, treatment withdrawal was due to infec­
tion and/or prolonged BM hypoplasia. These patients were 
not randomized for maintenance; 7 patients received hetero­
geneous therapy as maintenance, whereas 9 had no further 
treatment. The median remission duration of patients in this 
group is 23 months (range, 2 to 33).
The results of the RT-PCR studies peformed at diagnosis, 
after induction, and after consolidation in the whole series 
are shown in Table 5. The three patients who tested PCR-
it the end of consolidation 
BMT from an HLA-identical sibling. Of the 159 who tested 
PCR-negative, 14 went off the study for protocol violation 
(9 cases), treatment-related toxicity (4 cases), and refusal to 
continue the therapeutic program (1 case). The remaining 
145 patients were randomized for maintenance and are eur- 
enlly under evaluation for (he effect of the different treat­
ment approaches on relapse-lree survival.
As of March 1996, 17 patients relapsed at 5 to 20 months 
from the achievement of hematologic remission. Among 
these, two had not completed all cycles of consolidation 
chemotherapy. Fifteen had typical hypergranular morphol­
ogy at presentation, whereas two were classified as M3v. 
The median WBC count in these series of 17 patients was
i
Table 5. PCR Monitoring of PML/RAR«?
m i . u m m
Evaluable PCR i (%) PCR (%)
*£*•>
At diagnosis 
After induction 
After consolidation
247
139
162
247 (100%) 
55 (39.5%) 
3 (2%)
84 (60.5%) 
159 (98%)
7.2 X 10 /L (0.9 to 54.9). The type of breakpoint within the 
PML gene, available in 16 cases, was her 1-2 in nine patients, 
and her 3 in seven patients.
The estimated 12 and 24 months OS for all of the 253
e patients was 1 % and 877, Ifr«-«..-* 2%, whereas
the EFS was calculated at 83% ± 2.6% and 79% ± 3.2%,
•ison of EFS (calculated
patients who were
1). The
from the achievement of CR) 
PCR-positive and PCR-negative at end ol « «
¡id no statistically significant difference.
PtB a t  r i s k
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Fig 1, Kaplan-Meier estimates of overall survival and event-free 
survival (EFS).
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Table 6. Clinical Features of Patients With Overt or "Definitely Present1' ATRA Syndrome
UPN Age/Sex FAB Initial
WBC Count (X10”/L)
Peak 
(day of treatment) Therapy Outcome
07006 63/F M3 0.5 5.9 (6) ATRA discont./Dexamet. CR
24009 46/M M3v 54.2 101.0 (2) ATRA discont./Dexamet. CR
24010 36/F M3 7.2 18.2 (4) ATRA discont/Dexamet. CR
35005 45/M M3 11.6 25.8 (7) ATRA discont./Dexamet. CR
55003 40/F M3 0.6 1.6 (16) ATRA discont./Dexamet. CR
24001 31/F M3 1.5 5.1 (4) ATRA discont./Dexamet Died
Abbreviation: discont./Dexamet, discontinuation/Dexamethasone.
ATRA syndrome and other therapy-related toxicity. Of
■w X  * • '
240 patients evaluable for induction therapy, 6 (2.5%) devel­
oped an overt or “ definitely present” ATRA syndrome and 
one patient died of it. Clinical features including WBC initial 
count and peak, specific treatment for the syndrome, and 
outcome of these patients are reported in Table 6. In 11 
additional cases, a combination of signs and symptoms was 
observed, which allowed us to classify them as having “ in­
determinate” ATRA syndrome. Finally, ATRA syndrome 
was considered “ definitely absent” in 223 of 240 patients 
(93%).
Other ATRA-related adverse reactions included mucosal 
and skin dryness (29% of cases), hypotension (7%), head­
ache (13%), severe bone pain (6%), pseudotumor cerebri 
(2%), and hypercholesterolemia (6%). Scrotal ulcerations 
were observed in two patients ( 1%).
As to the other therapy-related toxicity, mainly due to
ence gained as a referral laboratory for RT-PCR analysis in 
a multicentric study,26 we put special emphasis on the logistic 
organization of the molecular studies. In particular, we rec­
ommended that rapid isolation and storage of the mononu­
clear (MNC) cell fraction of marrow aspirates in an RNAase 
inhibitor (guanidium isothiocyanate), be performed locally 
in each participating center before shipment. This procedure 
turned out to be extremely important for the extraction of 
good quality RNA in the vast majority of cases.
The results of induction therapy with ATRA and Idaru- 
bicin show that all PML/RARa positive patients are respon­
sive to this treatment. As a genetic diagnosis of APL was 
not required in any previously published study, it might seem 
inappropriate to compare our data with results obtained using 
other protocols, whether they included ATRA or not. How­
ever, it is conceivable that the lower CR rate reported in 
other studies could have been due, at least in part, to PML/
anthracycline treatment, these were limited to stomatitis RARa negative patients being enrolled.12"25'28'30 Several new
(6%), hemorrhages (15%), nausea and vomiting (5%), diar­
rhea (2%), cardiac (2.5%), hepatic (3%), and renal (0.5%)
toxicities considering together only World Health Organiza­
tion (WHO) grades 3 and 4.
Of the 5 deaths occurring after the end of induction, 3 
were recorded during the first consolidation course and 2 
during the second course. Three deaths were due to bacterial 
infection, one to hepatitis, and one to an ATRA syndrome 
developed in CR.
acute leukemia entities, which morphologically resemble 
typical APL but manifest distinct genetic and/or immunophe- 
notypic features, have been described recently. They include 
cases with variant translocation that involve RARa on 17q- 
with partner chromosomes other than 15, for example 
t(l l;17) and t(5; 17) associated APL,31,32 as well as cases 
with a myeloid-natural killer (CD56+) immunophenotype. 
Because these cases do not express the PML/RARa: fusion
DISCUSSION
Of all acute leukemias, APL is at present the form to 
which molecular studies contribute the most clinically rele­
vant information. Three lines of evidence support this as­
sumption, ie, ( I) the PML/RAR« genetic lesion is absolutely 
APL-speciiic and found in virtually 100% of cases2'4; (2) the 
disease responds specifically to a distinct treatment approach 
that is also effective against the life-threatening coagulopa­
thy'"4; and (3) PML/RARa detection in the leukemic blasts 
predicts response to ATRA.6 A similar combination of cir­
cumstances is not observed in any other human leukemia.
The mandatory prerequisite for entry into this study was 
molecular or cytogenetic evidence of the t(15; 17) in leuke­
mia cells at diagnosis. The characterization of the PML/ 
RARce junction type, available in 247 of 253 (98%) eligible 
patients, also provided an ideal specific marker for the sensi­
tive assessment of response to therapy. Based on past experi-
gene and rail to respond to ATRA, patients with no cytoge­
netic or molecular proof of the t( 15; 17) in their leukemia 
blasts at presentation were excluded from our series (Table 
1 ).
The AIDA induction regimen appears to be well tolerated. 
In fact, the incidence and the severity of complications, in­
cluding hemorrhagic deaths, ATRA syndrome, and other 
therapy-related toxicity were lower in our series than in other 
induction protocols irrespective of whether or not they in­
cluded ATRA .12'253,30 The combination of a differentiating 
agent and a cytotoxic drug administered in the early phase 
of therapy very likely provided a counteraction against either 
the bleeding diathesis due to the coagulopathy or the occur­
rence of the severe pulmonary symptoms associated with 
the ATRA syndrome. Several investigators have shown that 
ATRA treatment significantly improves the APL-associated 
coagulopathy,34'36 while cytotoxic chemotherapy is known 
to prevent the onset of the ATRA syndrome, being often 
anticipated in patients considered at risk because of hyper-
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leukocytosis at presentation.21 These two severe complica­
tions, which so far represented the major causes of induction 
death in APL, were recorded in a minority of cases in this 
study. Overall, 11 of 240 parients (5%) died during induction
treatment.
Following the guidelines of the New York Group (Frankel 
et al28and previous personal communication by Dr R.P. War- 
rell Jr, April 1993), we recommended to all physicians of 
our Cooperative Group to promptly administer I V dexameth- 
asone as prophylactic treatment at the earliest clinical sign 
of dyspnea. It is conceivable that, in conjunction with early
contributed to pre­
vent the onset of a full-blown and life-threatening ATRA 
syndrome in the vast majority of our patients.
st rat ion,
suggest that
consolidation, our clinical
of
f4 ar data
treat-
achieve PCR negativity, it is too early to predict the long­
term outcome in the present series. However, the actuarial 
1- and 2-year EFS estimates (83% ±  2.6% and 79% ±  3.2%, 
respectively) are promising figures with respect to long-term 
outcome. In addition, APL patients who relapse are easily 
rescued into second remission and become long-term survi­
vors more often than patients with other myeloid leuke-
nmias.
In conclusion, our results indicate that a specific treatment 
approach targetted to a molecular abnormality might dramat­
ically change the natural history of APL, turning this once 
rapidly fatal disease into one of the most frequently curable 
acute leukemias. In addition, APL offers a model that should 
trigger interest to identify other genelieo-dinical subsets of 
acute leukemia so that currently available therapy and future 
advancements can be more precisely directed at treating
ment might be considered in the future, at least for elderly 
patients. In fact, as shown in Table 4, the median age of 
patients withdrawn from the study because of therapy-related 
toxicity was 61 years. Furthermore, the preliminary follow-
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PCR results between consolidation cycles, although only 
available in a fraction of cases, indicate that the vast majority 
of patients achieve molecular remission after two cycles. 
A prolonged follow-up analysis is needed to establish the 
prognostic significance of these early achieved molecular 
remissions and to verify whether less postremission treat­
ment could be effective in APL, regardless of age.
Molecular remission was achieved in 60% of our cases 
after induction and 98% after consolidation. We are not sure 
whether the PCR positivity detected at the end of induction 
reflects persistence of resistant blasts or delayed ATRA- 
induced maturation. We are also unable to assess whether 
the different kinetics of molecular response and leukemia- 
cell clearance have prognostic value. However, the attain­
ment of a remission status corresponding to less than 10..1
PML/RAR«-positive cells (according to the sensitivity of 
our assay ) in almost all patients is further testimony for the 
therapeutic efficacy of the AIDA regimen.
While PCR positivity during hematologic remission in 
APL is generally considered a strong predictor of clinical 
relapse, the achievement of a PCR-negative status is no guar­
antee of cure, as indicated by the 17 relapses occurring in 
patients who had previously tested PCR-negative. This prob­
ably reflects the limited sensitivity of the RT-PCR assay for 
PML/RARce.'1 At the time of the present analysis, due to the 
low number of adverse events, no predictive features could 
be found that were associated with a higher probability of 
relapse. In particular, no statistically significant association 
was found between treatment outcome and type of PML 
breakpoint, WBC count, or PCR status after induction. How­
ever, it is interesting to observe that patients who relapsed 
had higher median WBC counts at diagnosis. Future analysis 
of these parameters in a larger series and on a longer follow-
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